In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Radiosurgery Alone as the Primary Treatment for Brain Metastases over 20 Centimeters

    Final Number:
    1339

    Authors:
    Ashley Grosvenor Tian MD; Robert Edward Lieberson MD, FACS; Griffith R. Harsh MD; Iris C. Gibbs MD; Scott G. Soltys MD; Steven D. Chang MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2011 Annual Meeting

    Introduction: Stereotactic radiosurgery (SRS) is effective for most brain metastases less than 3 cm diameter (approximately 15cc). Larger metastases are well managed with surgery followed by adjuvant radiation or SRS. Patients with large metastases, who are not surgical candidates, have had few options.

    Methods: Between 2002 and 2010, we treated 21 patients with solid metastases over 20 cc’s using SRS alone. We retrospectively analyzed demographics, diagnostic information, treatment parameters, and outcome data.

    Results: There were 15 men and 6 women aged 22 to 94 (median 63 ± 19). Lesion volumes ranged from 20.4 to 56.7 cc (median 23.8 ± 8.3). Lesion diameter ranged from 4.1 to 8.3 cm (5.0 ± 0.1). Pathologies included melanoma (4), lung (2), renal (2), prostate (2), germ cell (2), parotid (2), nasopharyngeal (2), colon, squamous cell, adenoid cystic, teratocarcinoma, and unknown primary (2). Survival varied from 3 days to greater than 9 years (median 0.4 ± 1.9 years) with one still alive 9 years after treatment. Seven patients were noted to have an increase in tumor size or tumoral edema (31.8%). Two of these required craniotomy. Five patients had stable tumor size (23.8%) and four showed improvement in tumor size and neurologic function (19%). Six patients had no post-treatment imaging or were lost to follow-up. There were no treatment related complications or deaths.

    Conclusions: Some metastases larger than 20 cc can be safely treated with SRS alone. Outcomes were best for those with a radiosensitive lesion, those with locally invasive lesions, and those with high pretreatment Karnofsky scores.

    Patient Care: Patients who could not previously be treated using SRS may benefit from improvement of symptoms and palliation.

    Learning Objectives: Participants should be able to describe the benefits of treating larger lesions with SRS.

    References: Yang, H., H.et al (2011). What factors predict the respone of larger brain metastases to readiosurgery? Neurosurgery. 68:682-690. Muacevic, A. Et al (2010). Feasibility, safety and outcome of frameless image-guided robotic radiosurgery for brain metastases. J Neurooncology. 97:267-274.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy